Erudio Healtherudio.com
Sponsor
MediLink Therapeutics (Suzhou) trials: what clinicians said in public
No HCP commentary report on a trial sponsored by MediLink Therapeutics (Suzhou) yet. Erudio has found public clinician commentary on 3 clinical trials sponsored by MediLink Therapeutics (Suzhou): INT-101-01, NCT06394414 and TAISHAN-302. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (MediLink Therapeutics (Suzhou) Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| TAISHAN-302 NCT06612151 · MediLink Therapeutics (Suzhou) Co., Ltd. DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| INT-101-01 NCT05434234 · MediLink Therapeutics (Suzhou) Co., Ltd. FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| NCT06394414 NCT06394414 · MediLink Therapeutics (Suzhou) Co., Ltd. FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||